Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPAD trial of higher versus standard immunoglobulin dosing in primary antibody deficiency
NL-OMON60685Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of subcuvia in Primary antibody deficiency (PAD) (2 arms), sponsored by University Medical Center Utrecht. Started Jul 2024; status: completed.
02
Drugs
subcuvia
03
Conditions
Primary antibody deficiency (PAD)
Beyond the preview
Go deeper on NL-OMON60685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60685.